[1]邱文瀚,王德娟,胡成,等.长链脂酰辅酶A合成酶3介导Akt信号通路调控前列腺癌进展的研究[J].中华腔镜泌尿外科杂志(电子版),2018,12(01):57-62.[doi:10.3877/cma.j.issn.1674-3253.2018.01.015 ]
　Qiu Wenhan,Wang Dejuan,Hu Cheng,et al.Long-chain acyl-CoA synthetase 3 induces Akt signaling pathway that regulate the progression of prostate cancer[J].,2018,12(01):57-62.[doi:10.3877/cma.j.issn.1674-3253.2018.01.015 ]
点击复制

长链脂酰辅酶A合成酶3介导Akt信号通路调控前列腺癌进展的研究()
分享到：

中华腔镜泌尿外科杂志(电子版)[ISSN:1006-6977/CN:61-1281/TN]

卷:
12卷
期数:
2018年01期
页码:
57-62
栏目:
实验研究
出版日期:
2018-01-31

文章信息/Info

Title:
Long-chain acyl-CoA synthetase 3 induces Akt signaling pathway that regulate the progression of prostate cancer
作者:
邱文瀚; 王德娟; 胡成; 黄文涛; 张慧敏; 何建文; 李一渊; 邱剑光; 李科
510630 广州，中山大学附属第三医院泌尿外科
Author(s):
Qiu Wenhan;  Wang Dejuan;  Hu Cheng;  Huang Wentao;  Zhang Huimin;  He Jianwen;  Li Yiyuan;  Qiu Jianguang;  Li Ke.
Department of Urology, the Third Affiliated Hospitalof Sun Yat-sen University, Guangzhou 510630, China
关键词:
前列腺癌;  长链脂酰辅酶A 合成酶3;  信号通路;  细胞增殖
DOI:
10.3877/cma.j.issn.1674-3253.2018.01.015
摘要:
目的 研究长链脂酰辅酶A 合成酶3（ACSL3）表达对前列腺癌（PCa）细胞增殖能力的影响，探索ACSL3 调控PI3K/Akt/MMP-9 信号通路的分子机制，发掘ACSL3 预测前列腺癌复发进展的临床应用价值。方法 利用Western blot 检测ACSL3 在不同前列腺癌细胞系中的表达；构建稳定表达ACSL3 的PCa 细胞株，利用MTT 法检测过表达ACSL3 对PCa 细胞增殖的改变；Western blot 检测过表达ACSL3 对PCa 细胞中Akt，磷酸化Akt（p-Akt），基质金属蛋白酶9（MMP-9）表达水平的影响；通过免疫荧光染色实验探索ACSL3 与Akt 蛋白之间是否可能存在共定位；利用免疫组织化学法（IHC）比较不同Gleason 评分患者中ACSL3 的表达差异。结果 Western blot 检测显示ACSL3 蛋白在局限性前列腺癌细胞22Rv1 中存在着特异性的低表达，同时，ACSL3 蛋白在激素非依赖性前列腺癌细胞中较激素依赖性前列腺癌细胞表达量更高。MTT 实验表明过表达ACSL3 后癌细胞增殖能力明显增强。此外，Western blot 显示过表达ACSL3 后p-Akt、MMP-9 表达均明显上调；激光共聚焦显微镜下，免疫荧光染色显示ACSL3 与Akt 存在着蛋白共定位关系。临床检测中，IHC 显示ACSL3 表达量随Gleason 评分升高而增加。结论 ACSL3 可能通过与Akt 蛋白间的相互作用，介导PI3K/Akt/MMP-9 信号通路的激活，影响PCa 细胞增殖。此外，ACSL3 的表达与前列腺癌的Gleason 评分具有相关性，可能影响患者预后。

参考文献/References:

[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[2] Cooper LA, Page ST. Androgens and prostate disease[J]. Asian J Androl, 2014, 16(2): 248-255.
[3] Saad F, Fizazi K. Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration-resistant prostate cancer[J]. Urology, 2015, 86(5):8 52-861.
[4] Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion[J]. Nat Clin Pract Urol, 2009, 62():76-85.
[5] Galletti G, Leach BI, Lam L, et al. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cnacer[J].Cancer Treat Rev, 2017, 57: 16-27.
[6] Ceder Y, Bjartell A, Culig Z, et al. The molecular evolution of castration-resistant prostate cancer[J]. Eur Urol Focus, 2016,2 (5):506-513.
[7] Marques RB, Dits NF, Erkens-Schulze S, et al. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines[J]. PLoS One, 2011, 6(8): e23144.
[8] Obinata D, Takayama K, Fujiwara K, et al. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth[J]. Oncogene, 2016, 35(49): 6350-6358.
[9] Yan S. Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: An update[J]. World J Gastroenterol, 2015, 21(12): 3492.
[10] Uddin S, Siraj AK, Al-Rasheed M, et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers[J].J Clin Endocrinol Metab, 2008, 93(10): 4088-4097.
[11] 李科, 陈怡, 董艳, 等. ACSL3 在前列腺癌细胞系中的表达及其对前列腺癌转移的影响[J]. 中国病理生理杂志, 2014, 30 (2): 250-255.
[12] 彭叔彬, 曾花, 邱剑光, 等. ENDOD1 在前列腺癌组织及细胞中的表达及意义[J]. 中国病理生理杂志, 2017, 33(1): 7-12.
[13] Yu S, Xu Z, Zou C, et al. Ion channel TRPM8 promotes hypoxic growth of prostate cancer cells via an O2 -independent and RAC1Kmediated mechanism of HIF-1alpha stabilization[J]. J Pathol, 2104,234(4): 514-525.
[14] Sridhar SS, Freedland SJ, Gleave ME, et al. Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment[J].European Urology, 2014, 65(2): 289-299.
[15] Karantanos T, Evans CP, Tombal B, et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level[J]. Eur Urol, 2015, 67(3): 470-479.
[16] Lin HK, Yeh S, Kang HY, et al. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor[J].Proc Natl Acad Sci U S A, 2001, 98(13): 7200-7205.
[17] Marques RB, Aghai A, de Ridder CM, et al. High efficacy of combination therapy using pi3k/akt inhibitors with androgen deprivation in prostate cancer preclinical models[J]. Eur Urol ,2015,67(6): 1177-1185.
[18] Thomas C, Lamoureux F, Crafter C, et al. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo[J]. Mol Cancer Ther, 2013, 12(11): 2342-2355.
[19] Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies[J]. Lancet, 2007, 369(9574): 1742-1757.
[20] Mitra R, Le TT, Gorjala P, et al. Positive regulation of protset acancer cell growth by lipid droplet forming and processing enzymes DGTA1 and ABHD5[J]. BMC Cancer, 2017, 17(1): 631.
[21] Yue S, Li J, Lee SY, et al. Cholesteryl ester accumulation incdeud by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness[J]. Cell Metab, 2014, 19(3): 393-406.
[22] Migita T, Takayama KI, Urano T, et al. ACSL3 promotes intratumroal steroidogenesis in prostate cancer cells[J]. Cancer Sci, 2017，108(10): 2011-2021.
[23] Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications[J]. J Clin Oncol, 2000, 18(5): 1135-1149.
[24] Cheng CY, Hsieh HL, Hsiao LD, et al. PI3-K/Akt/JNK/NF-kappaB is essential for MMP-9 expression and outgrowth in human limbal epithelial cells on intact amniotic membrane[J]. Stem Cell Res ,2012,9(1): 9-23.

相似文献/References:

[1]周建华,高新,蔡育彬,等.腹腔镜前列腺癌根治术126例3年随访结果[J].中华腔镜泌尿外科杂志(电子版),2007,(01):22.
　ZHOU Jian-hua,GAO Xin,CAI Yu-bin,et al.Results of study of 126 cases underwent laparoscopic radical Prostatectomy during three years' follow-up[J].,2007,(01):22.
[2]关健强,周少丽,龚楚链,等.腹腔镜下前列腺癌根治术中呼气末CO2分压的变化及意义[J].中华腔镜泌尿外科杂志(电子版),2008,(03):37.
　GUAN Jian-qiang,ZHOU Shao-li,GONG Chu-lian,et al.Difference between arterial and end-tidal carbon dioxide pressures in laparoscopic radical prostarectome[J].,2008,(01):37.
[3]乔鹏,邢念增.经腹膜外腹腔镜前列腺癌根治术(附9例报告)[J].中华腔镜泌尿外科杂志(电子版),2009,(01):25.
　QIAO Peng,XING Nian-zeng.Extraperitoneal laparoscopic radical prostatectomy: a report of 9 cases[J].,2009,(01):25.
[4]进展,孙其鹏,高新.TMPRSS2-ETS融合基因在前列腺癌研究的进展[J].中华腔镜泌尿外科杂志(电子版),2009,(04):354.
[5]黄海,杜涛,黄健,等.高效抑制核因子κ-B的茎环RNA基因序列的获得[J].中华腔镜泌尿外科杂志(电子版),2009,(05):444.
[6]高新,邱剑光,周祥福,等.腹腔镜前列腺癌根治术5年随访结果——中国单中心170例报道[J].中华腔镜泌尿外科杂志(电子版),2010,(01):2.
　GAO Xin,QIU Jian-guang,ZHOU Xiang-fu,et al.Laparoscopic radical prostatectomy:oncological and functional results of 170 patients with a minimum 5-year follow-up[J].,2010,(01):2.
[7]刘伟鹏,庞俊,李辽源,等.前列腺癌CRMP4基因启动子甲基化研究[J].中华腔镜泌尿外科杂志(电子版),2010,(01):57.
　LIU Wei-peng,PANG Jun,LI Liao-yuan,et al.A study on promoter methylation of CRMP4 in prostate cancer[J].,2010,(01):57.
[8]孙其鹏,庞俊,李辽源,等.荧光原位杂交技术在前列腺癌诊断中的临床应用[J].中华腔镜泌尿外科杂志(电子版),2010,(01):64.
　SUN Qi-peng,PANG Jun,LI Liao-yuan,et al.Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the diagnosis of prostate cancer[J].,2010,(01):64.
[9]蒲小勇,陆敏华,高新,等.不同穿刺针数经直肠前列腺穿刺活检诊断前列腺癌的研究[J].中华腔镜泌尿外科杂志(电子版),2010,(05):347.
　PU Xiao-yong,LU Ming-hua,GAO Xin,et al.Comparative study of the different cores using transrectal prostate biopsy in diagnosis of prostate cancer[J].,2010,(01):347.
[10]刘小彭,高新,周祥福,等.耻骨后前列腺癌根治术联合内分泌治疗T3N1期前列腺癌[J].中华腔镜泌尿外科杂志(电子版),2010,(05):374.
　LIU Xiao-peng,GAO Xin,ZHOU Xiang-fu,et al.Radical prostatectomy combining with adjuvant hormone therapy for treatment of prostate cancer with pelvic lymph node metastasis[J].,2010,(01):374.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金资助项目（81402111）；广州市科技计划“珠江科技新星”科技创新人才专项（201710010039）；广东省科技计划项目（2017A020215028）；中山大学青年教师培育项目（17ykpy48）
通讯作者：李科，Email: like35@sysu.edu.cn
更新日期/Last Update: 2018-02-25